Emcure Pharmaceuticals officially stepped into India’s fast-growing anti-obesity segment with the launch of Poviztra, a semaglutide-based injectable therapy for chronic weight management. The launch marks a strategic collaboration with Danish drugmaker Novo Nordisk and positions Emcure among the leading contenders in the country’s rapidly evolving weight-loss market.
Poviztra will serve as a second brand of Novo Nordisk’s globally popular obesity drug, Wegovy. With obesity and lifestyle-related disorders rising sharply in India, the market is expected to witness intense competition over the next few years.
Competitive Pricing Strategy to Drive Adoption
To strengthen its market position, Emcure has introduced Poviztra at a competitive price point. The once-weekly injectable pen device will be available in five dosage strengths, ranging from 0.25 mg to a maintenance dose of 2.4 mg. The monthly cost for the starter dose — comprising four weekly injections — has been fixed at ₹8,790. This makes Poviztra nearly 19% cheaper than Wegovy, which is priced at ₹10,850 for the same starting dosage.
Additionally, Poviztra is significantly more affordable than Mounjaro and Yurpeak, marketed through partnerships involving Eli Lilly and Company and Cipla Limited. These therapies currently cost between ₹14,000 and ₹27,500 per month.
India’s Anti-Obesity Market Gains Momentum
India’s anti-obesity drug market is presently valued at around ₹1,047 crore and continues to expand rapidly as awareness around obesity management increases. Currently, Mounjaro dominates the segment with a moving annual turnover of nearly ₹496 crore. In contrast, Wegovy, which entered India in June 2025, has recorded sales of approximately ₹49 crore so far. Against this backdrop, Emcure aims to carve out a sizeable share by combining aggressive pricing with a deep nationwide distribution network.
Strategic Partnership With Novo Nordisk
Emcure Pharmaceuticals has secured exclusive rights to distribute and commercialise Poviztra in India for chronic weight management. The collaboration allows Emcure to market an innovator molecule backed by more than a decade of global clinical data, instead of relying on a generic or biosimilar version. Novo Nordisk will continue supplying the imported drug, while also independently marketing Ozempic for type-2 diabetes treatment.
Building Brand Recall Before Patent Expiry
Emcure’s entry into the market comes at a strategically important time. The patent for semaglutide is expected to expire in March 2026, opening the door for a flood of generic launches. Company executives estimate that nearly 50 players could eventually enter the category after patent expiry. By partnering early with Novo Nordisk, Emcure aims to establish strong brand visibility and customer trust ahead of intensified competition. As reported by multibagg.ai, according to Vikas Madan Thapar, President of Corporate Development at Emcure, the partnership provides an opportunity to shape the market early rather than getting lost in a crowded generic landscape later.
Expanding Beyond Metro Cities
Unlike many premium therapies that remain concentrated in metropolitan regions, Emcure plans to make Poviztra accessible across India, including Tier-2 and Tier-3 cities. Managing Director and CEO Satish Mehta highlighted that the company’s extensive reach beyond metros played a key role in Novo Nordisk selecting Emcure as its partner.
To support the nationwide rollout, Emcure will initially deploy a field force of more than 1,000 personnel. The team will focus on specialties including cardiology, endocrinology, women’s health, and internal medicine, helping the company strengthen awareness and adoption across diverse healthcare markets.
